title: Fidaxomicin for the treatment of Clostridium difficile infections.
abstract: Clostridium difficile infection (CDI), also known as C. difficile-associated disease or diarrhoea (CDAD), is an important cause of hospital-acquired diarrhoea with disease severity ranging from mild diarrhoea to fulminant colitis. In addition, over 40% of new cases of CDI occur outside hospital. ▾ Fidaxomicin (Dificlir - Astellas), the first antibiotic in a new class called macrocyclics, has recently been licensed for the treatment of C. difficile infection in adults. Here we provide a brief overview of C. difficile infection and assess how fidaxomicin fits with current management strategies for treatment of such infections.
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000617:Aminoglycosides / Q000008:administration & dosage* / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016360:Clostridioides difficile / Q000302:isolation & purification; D003015:Clostridium Infections / Q000150:complications / Q000188:drug therapy*; D003967:Diarrhea / Q000188:drug therapy* / Q000209:etiology; D000077732:Fidaxomicin; D006801:Humans; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077732:Fidaxomicin